China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway

China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Miranda McLaren · 2026-08-06

China is becoming a global hub for oncology trials, with the NMPA now offering expedited review pathways for INDs.

Source: Pharmaceutical Technology